Helix BioPharma Management
Management criteria checks 1/4
Helix BioPharma's CEO is Jacek Antas, appointed in Dec 2022, has a tenure of 2.08 years. total yearly compensation is CA$267.28K, comprised of 24.3% salary and 75.7% bonuses, including company stock and options. directly owns 1.3% of the company’s shares, worth CA$568.10K. The average tenure of the management team and the board of directors is 1.6 years and 2.1 years respectively.
Key information
Jacek Antas
Chief executive officer
CA$267.3k
Total compensation
| CEO salary percentage | 24.3% |
| CEO tenure | 2.1yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.1yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2024 | n/a | n/a | -CA$9m |
| Jul 31 2024 | n/a | n/a | -CA$9m |
| Apr 30 2024 | n/a | n/a | -CA$6m |
| Jan 31 2024 | n/a | n/a | -CA$6m |
| Oct 31 2023 | n/a | n/a | -CA$6m |
| Jul 31 2023 | CA$267k | CA$65k | -CA$6m |
Compensation vs Market: Jacek's total compensation ($USD185.60K) is about average for companies of similar size in the Canadian market ($USD166.88K).
Compensation vs Earnings: Insufficient data to compare Jacek's compensation with company performance.
CEO
Jacek Antas
2.1yrs
Tenure
CA$267,278
Compensation
Mr. Jacek Antas serves as Chief Executive Officer and Director of Helix BioPharma Corp. since December 08, 2022 and serves as its Chairman. He serves as a Director of Helix BioPharma Corp. since April 18,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 2.1yrs | CA$267.28k | 1.3% CA$ 568.1k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of R&D | 2.3yrs | no data | no data | |
| Director of ADC Discovery | 1.1yrs | no data | no data |
1.6yrs
Average Tenure
Experienced Management: HBP's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 2.8yrs | CA$267.28k | 1.3% CA$ 568.1k | |
| Independent Director | 2.8yrs | no data | 0.85% CA$ 370.8k | |
| Independent Director | 2.1yrs | no data | no data | |
| Independent Director | 1.4yrs | no data | no data | |
| Independent Director | 2.1yrs | no data | no data |
2.1yrs
Average Tenure
Experienced Board: HBP's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 07:28 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Helix BioPharma Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | Merriman Capital, Inc |
| Ahu Demir | NOBLE Capital Markets, Inc. |